The Korea Times close
National
  • Politics
  • Diplomacy
  • Defense
  • Labor & Environment
  • Law & Crime
  • Health & Welfare
  • Embassy
  • Seoul & Provinces
  • Education
  • Foreign Communities
  • Obituaries
  • Multicultural Youth Award
Biz & Tech
  • Auto
  • IT
  • Game
  • Manufacturing
  • Retail & Food
  • Energy
  • Construction
  • Airlines
Finance
  • Policies
  • Economy
  • Markets
  • Banks
  • Non-banks
  • Economic Essay Contest
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to the Editor
Lifestyle
  • Arts
  • Books
  • Travel & Cuisine
  • Trend
  • Fashion
  • Around Town
  • Fortune Telling
Entertainment
  • K-pop
  • K-dramas & Shows
  • Movies
  • Music
  • Performances
  • Asia Model Festival
Sports
  • Football
  • Golf
  • Baseball
  • Other Sports
World
  • Asia Pacific
  • Americas
  • Europe & Africa
  • SCMP
Video
  • On the Spot
  • Feature
  • News
Photos
  • Photo News
  • Darkroom
Community
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
World
  • Asia Pacific
  • Americas
  • Europe & Africa
  • SCMP
Fri, January 15, 2021 | 23:53
Americas
Chinese coronavirus vaccine shows 50% efficacy in Brazil
Posted : 2021-01-13 10:48
Updated : 2021-01-13 10:48
Mail
Print Preview
Font Size Up
Font Size Down
An employee picks up a vial containing CoronaVac, Sinovac Biotech's vaccine against the coronavirus disease (COVID-19) at Butantan biomedical production center in Sao Paulo, Brazil, Jan. 12, 2021. Reuters
An employee picks up a vial containing CoronaVac, Sinovac Biotech's vaccine against the coronavirus disease (COVID-19) at Butantan biomedical production center in Sao Paulo, Brazil, Jan. 12, 2021. Reuters

The Chinese-developed Coronavac Covid-19 vaccine has demonstrated a 50 percent efficacy following tests in Brazil, the organization in charge of its production in the South American country said on Tuesday.

Coronavac has been given to frontline health care workers in close contact with coronavirus patients.

The Butantan Institute repeated its claim from last week that the vaccine is 78 percent effective in mild cases that needed treatment and showed 100 percent efficacy in moderate to serious cases.

"It's a safe, effective vaccine that ticks all the boxes to justify its use in an emergency," said Butantan director Dimas Covas.

The trial, which was used on 12,500 volunteers, did not produce any adverse effects or significant allergic reactions.

"If the vaccine resisted this test, it's going to work infinitely better on a community level," said Ricardo Palacios, the medical manager for clinical trials at Butantan, which is owned by Sao Paulo state and is the largest producer of vaccines in Latin America.

Although the vaccine has reached the minimum efficacy target of 50 percent set by the World Health Organization, it is well behind other vaccines produced by Moderna (94 percent) and Pfizer/BioNTech (95 percent).

Last Friday, Butantan presented the first vaccine authorization request to Brazil's health regulatory body ANVISA.

It was followed just a few hours later by a request from the AstraZeneca/Oxford vaccine makers.

Coronavac has been at the center of a political dispute between President Jair Bolsonaro, who has repeatedly tried to discredit it, and its backer Sao Paulo state governor Joao Doria, who is expected to challenge the incumbent at next year's presidential election.

Brazil has recorded more than 203,000 deaths from Covid-19 and over eight million cases among its 212 million population.

Since November it has witnessed a second wave of infections.

Sao Paulo state is due to begin immunizing its 12 million citizens from January 25. Beijing has already sent 10.7 million Coronavac doses and the supplies needed to make another 40 million doses. (AFP)


Indonesia begins coronavirus vaccination campaign with Widodo
Indonesian President Joko Widodo on Wednesday received the first shot of a Chinese-made COVID-19 vaccine after Indonesia approved it for emergency use and began efforts to vaccine ...









 
WooriBank
 
  • Korea's 1st Singaporean-style cafe stirs memories of ASEAN trips
  • Why do most Koreans want to avoid getting vaccinated first?
  • Supreme Court upholds 20-year prison term for former President Park Geun-hye
  • Second Trump impeachment [PHOTOS]
  • Trump impeached again
  • Number of hallyu fans around the world surpasses 100 million
  • Time to shift focus on arms control with North Korea: experts
  • Coupang Eats hot on heels of rival Yogiyo
  • Is inflation returning with economic rebound?
  • Why treatments unlikely to be 'game changer' in COVID-19 battle
  • BTS's Jungkook tops Amazon's international best seller chart with solo tracks BTS's Jungkook tops Amazon's international best seller chart with solo tracks
  • Anthology film 'Today, Together 2' reflects on meaning of family in modern Korea Anthology film 'Today, Together 2' reflects on meaning of family in modern Korea
  • Entertainers in hot seat over apartment noise Entertainers in hot seat over apartment noise
  • Chinese money flows into Korean culture industry amid streaming war Chinese money flows into Korean culture industry amid streaming war
  • (G)I-DLE tops iTunes charts in 51 countries with 'I burn' (G)I-DLE tops iTunes charts in 51 countries with 'I burn'
DARKROOM
  • Second Trump impeachment [PHOTOS]

    Second Trump impeachment [PHOTOS]

  • Pro-Trump rioters breach the US Capitol

    Pro-Trump rioters breach the US Capitol

  • Our children deserve better (Part 2)

    Our children deserve better (Part 2)

  • Migrants hard hit by COVID-19: UN migration agency

    Migrants hard hit by COVID-19: UN migration agency

  • Happy New Year 2021

    Happy New Year 2021

WooriBank
  • About Korea Times
  • CEO Message
  • Times History
  • Content Sales
  • Media Kit
  • Contact Us
  • Location
  • Privacy Statement
  • Terms of Service
  • Mobile Service
  • RSS Service
  • Ombudsman
  • hankookilbo
  • Dongwha Group
  • Code of Ethics
Copyright